Metabasis, Valeant Rise
Shares of drug developers Valeant Pharmaceuticals (VRX) and Metabasis Therapeutics (MBRX) jumped in after-hours trading Wednesday after the companies announced licensing agreements with drug giant Schering-Plough (SGP) for a new hepatitis B treatment.
Schering-Plough has licensed exclusive worldwide rights to develop and market the investigational treatment, pradefovir, for patients with chronic hepatitis B. Valeant initially licensed pradefovir from Metabasis in 2000 and has been evaluating the drug's safety and efficacy in treating the disease. The drug uses Metabasis' so-called HepDirect technology to direct higher drug concentrations into the liver, the primary site where the hepatitis B virus replicates.
"Pradefovir has the potential to offer improved treatment options for patients with chronic hepatitis B, a serious blood-borne infection affecting some 400 million people worldwide," said Dr. Robert Spiegel, chief medical officer of Schering-Plough Research Institute.
The transaction is expected to close in the first quarter of 2007, pending customary closing conditions. Under the terms of the deal, Schering-Plough will make upfront payments to Valeant and Metabasis and will pay additional fees to the companies upon the achievement of certain development and regulatory milestones.Schering-Plough will fund all future research and development activities including clinical studies and regulatory filings, and will pay both of the companies royalties if the drug enters the market. Valeant's shares gained 3.7% to $17.52 and Metabasis jumped 6.3% to $8.30 in after-hours trading, while Schering-Plough's shares were down 6 cents to $23.24.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV